Table 2 ER and PR proportion according to tumour characteristic in both Eritrean and Sudanese women
Tumour and biomarker characteristics | Eritrean | Sudanese | |||||||
|---|---|---|---|---|---|---|---|---|---|
ER positive | ER negative | ER positive | ER negative | ||||||
n | (%) | n | (%) | n | (%) | n | (%) | ||
Histologic type | IDCNST | 41 | 71.9% | 48 | 81.4% | 222 | 83.6% | 270 | 91.5% |
ILC | 10 | 17.5% | 1 | 1.7% | 15 | 5.7% | 3 | 1% | |
Others | 6 | 10.5% | 10 | 16.9% | 27 | 10.7% | 23 | 7.5% | |
Pathologic Tumour size | pT1 | 17 | 29.8% | 6 | 10.2% | 46 | 19.2% | 36 | 12.5% |
pT2 | 26 | 45.6% | 22 | 37.3% | 107 | 44.6% | 141 | 49.0% | |
pT3 | 10 | 17.5% | 27 | 45.8% | 50 | 20.8% | 68 | 23.6% | |
pT4 | 4 | 7.0% | 4 | 6.8% | 37 | 15.4% | 43 | 14.9% | |
Lymph node involvement | pN0 | 40 | 70.2% | 32 | 54.2% | 104 | 52.0% | 94 | 42.9% |
pN1 | 6 | 10.5% | 9 | 15.3% | 37 | 18.5% | 49 | 22.4% | |
pN2 | 8 | 14.0% | 8 | 13.6% | 36 | 18.0% | 42 | 19.2% | |
pN3 | 3 | 5.3% | 10 | 16.9% | 23 | 11.5% | 34 | 15.5% | |
Nottingham Grade | GI | 8 | 14.0% | 2 | 3.4% | 16 | 6.3% | 4 | 1.3% |
GII | 30 | 52.6% | 16 | 27.1% | 155 | 61.5% | 151 | 49.0% | |
GIII | 19 | 33.3% | 41 | 69.5% | 81 | 32.1% | 153 | 49.7% | |
PR | PR negative | 10 | 17.5% | 59 | 100.0% | 43 | 17.1% | 303 | 98.4% |
PR positive | 47 | 82.5% | 0 | 0.0% | 209 | 82.9% | 5 | 1.6% | |
HER 2 | Negative (0 and 1+) | 37 | 64.9% | 29 | 49.2% | 132 | 65.1% | 112 | 52.8% |
Negative (2+) | 6 | 10.5% | 10 | 16.9 | 20 | 9.8% | 32 | 15.1% | |
Positive (3+) | 14 | 24.6% | 20 | 33.9% | 51 | 25.1% | 68 | 32.1% | |